Lifeboat Foundation

A newly published study has described the successful results in mice of a novel vaccine designed to prevent neurodegeneration associated with Alzheimer’s disease. The researchers suggest this “dementia vaccine” is now ready for human trials, and if successful could become the “breakthrough of the next decade.”

The new study, led by the Institute for Molecular Medicine and University of California, Irvine, describes the effect of a vaccine designed to generate antibodies that both prevent, and remove, the aggregation of amyloid and tau proteins in the brain. The accumulation of these two proteins is thought to be the primary pathological cause of neurodegeneration associated with Alzheimer’s disease.

The research revealed the vaccine led to significant decreases in both tau and amyloid accumulation in the brains of bigenic mice engineered to exhibit aggregations of these toxic proteins. Many prior failed Alzheimer’s treatments over the past few years have focused individually on either amyloid or tau protein reductions, but growing evidence suggests a synergistic relationship between the two toxic proteins may be driving neurodegeneration. Hence the hypothesis a combination therapy may be the most effective way to prevent this kind of dementia.

A Mars invasion, a climate meeting and human–animal hybrids are set to shape the research agenda.

The second thing to mention is that in many instances, we actually have cracked it, at least medically. There are endless cutting-edge treatments being deployed as we speak, and endless additional cutting-edge research projects being conducted. There are new breakthroughs all the time, much of which are awaiting FDA approval, but one thing many of these treatments and cures have in common is that they are developed in a tiny country smaller than New Jersey that happens to be located in perhaps the worst neighborhood on Earth. When it comes to cancer research, Israel leads the way.

Finally, the last time I wrote about cutting-edge cancer treatments, I was contacted by a close friend who is a leading oncologist. He pointed out that a disclaimer is very much necessary when I write these articles. The last thing oncologists need is for their patients to think there is some magical solution here and show up to their appointments with a cut-out of an article. In fact, the last thing a cancer patient needs is false hope.

So the disclaimer is that this company is in the clinical trial phase, and if all goes according to plan, tumors might be much more manageable and treatable than they are today, but a lot has to happen before we get there.

Dr Shima Beigi BSc, MSc, MSc, Ph.D. founder of Mindfulness Engineering™️ and ideaXme Rich Connectedness™️ ambassador interviews Dr Jon Finn founder Tougher Minds.

Dr Jon Finn:

Continue reading “How To Build A Tougher Mind: Dr Jon Finn” »

“As an entrepreneur I like to know the next two or three things I might start a company on. For me it was robotics, bio-hacking, and quantum.”–whurley.

Sickle Cell Therapy With CRISPR Gene Editing Shows Promise : Shots — Health News NPR tells the exclusive, behind-the-scenes story of the first person with a genetic disorder to be treated in the United States with the revolutionary gene-editing technique CRISPR.

With new technology to edit genes, scientists are now working on things that once seemed impossible. But what are the boundaries? See the full 60 Minutes interview with Church, here: https://cbsn.ws/34ZhuTs

Watch Full Episodes of “60 Minutes” HERE: http://cbsn.ws/1Qkjo1F
Get more “60 Minutes” from “60 Minutes: Overtime” HERE: http://cbsn.ws/1KG3sdr
Relive past episodies and interviews with “60 Rewind” HERE: http://cbsn.ws/1PlZiGI
Follow “60 Minutes” on Instagram HERE: http://bit.ly/23Xv8Ry
Like “60 Minutes” on Facebook HERE: http://on.fb.me/1Xb1Dao
Follow “60 Minutes” on Twitter HERE: http://bit.ly/1KxUsqX
Follow “60 Minutes” on Google+ HERE: http://bit.ly/1KxUvmG

Continue reading “The complicated ethics of genetic engineering” »